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Abstract
Prostate cancer is the second most common cause of male cancer deaths in the United States. Here
we present the complete sequence of seven primary prostate cancers and their paired normal
counterparts. Several tumors contained complex chains of balanced rearrangements that occurred
within or adjacent to known cancer genes. Rearrangement breakpoints were enriched near open
chromatin, androgen receptor and ERG DNA binding sites in the setting of the ETS gene fusion
TMPRSS2-ERG, but inversely correlated with these regions in tumors lacking ETS fusions. This
observation suggests a link between chromatin or transcriptional regulation and the genesis of
genomic aberrations. Three tumors contained rearrangements that disrupted CADM2, and four
harbored events disrupting either PTEN (unbalanced events), a prostate tumor suppressor, or
MAGI2 (balanced events), a PTEN interacting protein not previously implicated in prostate
tumorigenesis. Thus, genomic rearrangements may arise from transcriptional or chromatin
aberrancies to engage prostate tumorigenic mechanisms.
Among men in the United States, prostate cancer accounts for more than 200,000 new
cancer cases and 32,000 deaths annually1. Although androgen deprivation therapy yields
transient efficacy, most patients with metastatic prostate cancer eventually die of their
disease. These aspects underscore the critical need to articulate both genetic underpinnings
and novel therapeutic targets in prostate cancer.
Recent years have heralded a marked expansion in our understanding of the somatic genetic
basis of prostate cancer. Of considerable importance has been the discovery of recurrent
gene fusions that render ETS transcription factors under the control of androgen-responsive
or other promoters2–5. These findings suggest that genomic rearrangements may comprise a
major mechanism driving prostate carcinogenesis. Other types of somatic alterations also
engage important mechanisms6–8; however, the full spectrum of prostate cancer genomic
alterations remains incompletely characterized. Moreover, although the androgen signaling
axis represents an important therapeutic focal point9,10, relatively few additional drug
targets have yet been elaborated by genetic studies of prostate cancer11. To discover
additional genomic alterations that may underpin lethal prostate cancer, we performed
paired-end, massively parallel sequencing on tumor and matched normal genomic DNA
obtained from seven patients with “high-risk” primary prostate cancer.
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Landscape of genomic alterations
All patients harbored tumors of stage T2c or greater, and Gleason grade 7 or higher. Serum
prostate-specific antigen (PSA) levels ranged from 2.1–10.2 ng/ml (Supplementary Table 1).
Three tumors contained chromosomal rearrangements involving the TMPRSS2-ERG loci as
determined by fluorescence in situ hybridization (FISH) and RT-PCR2 (Table 1 and
Supplementary Table 1). We obtained approximately 30-fold mean sequence coverage for
each sample, and reliably detected somatic mutations in more than 80% of the genome
(described in Supplementary Information). Circos plots12 indicating genomic
rearrangements and copy number alterations for each prostate cancer genome are shown in
Figure 1.
We identified a median of 3,866 putative somatic base mutations (range: 3,192–5,865) per
tumor; the estimated mean mutation frequency was 0.9 per megabase (see Supplementary
Methods). This mutation rate is similar to that observed in acute myeloid leukemia and
breast cancer13–16 but 7–15 fold lower than rates reported for small cell lung cancer and
melanoma17–19. The mutation rate at CpG dinucleotides was more than 10-fold higher than
at all other genomic positions (Supplementary Fig. 1). A median of 20 non-synonymous
base mutations per sample were called within protein-coding genes (range: 13–43;
Supplementary Table 3). We also identified six high-confidence coding indels (4 deletions,
2 insertions) ranging from 1 to 9 base pairs (bp) in length, including a 2bp frameshift
insertion in the tumor suppressor gene, PTEN (Supplementary Table 4, Supplementary Fig.
2).
Two genes (SPTA1 and SPOP) harbored mutations in 2/7 tumors. SPTA1 encodes a scaffold
protein involved in erythroid cell shape specification, while SPOP encodes a modulator of
Daxx-mediated ubiquitination and transcriptional regulation20. The SPOP mutations
exceeded the expected background rate in these tumors (Q = 0.055), Moreover, SPOP was
also found significantly mutated in a separate study of prostate cancer21. Interestingly, the
chromatin modifiers CHD1, CHD5, and HDAC9 were mutated in 3/7 prostate cancers.
These genes regulate embryonic stem cell pluripotency, gene regulation, and tumor
suppression22–24. Members of the HSP-1 stress response complex (HSPA2, HSPA5, and
HSP90AB1) were also mutated in 3/7 tumors. The corresponding proteins form a chaperone
complex targeted by several anticancer drugs in development25. Furthermore, we found the
KEGG pathway “Antigen processing and presentation” to be significantly mutated out of
616 diverse gene sets corresponding to gene families and known pathways (Q = 0.0021).
This result is intriguing given the clinical benefit associated with immunotherapy for
prostate cancer26,27. Other known cancer genes were mutated in single tumors, including
PRKCI and DICER. Thus, some coding mutations may contribute to prostate tumorigenesis
and suggest possible therapeutic interventions.
Complex patterns of balanced rearrangements
Given the importance of oncogenic gene fusions in prostate cancer, we next characterized
the spectrum of chromosomal rearrangements. We identified a median of 90 rearrangements
per genome (range: 43–213) supported by ≥3 distinct read pairs (Supplementary Table 5).
This distribution of rearrangements was similar to that previously described for breast
cancer28. We examined 594 candidate rearrangements by multiplexed PCR followed by
massively parallel sequencing, and validated 78% of events by this approach (see
Supplementary Methods). Three genes disrupted by rearrangements also harbored non-
synonymous mutations in another sample: ZNF407, CHD1, and PTEN. Notably, the
chromatin modifier CHD1, which contains a validated splice site mutation in prostate tumor
PR-1701 (as indicated above), also harbored intragenic breakpoints in two additional
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samples (PR-0508 and PR-1783). These rearrangements predict truncated proteins, raising
the possibility that dysregulated CHD1 may contribute to a block in differentiation in some
prostate cancer precursor cells22.
In 88% of cases, the fusion point could be mapped to base pair resolution (Supplementary
Methods). The most common type of fusion involved a precise join, with neither
overlapping nor intervening sequence at the rearrangement junction. In a minority of cases,
an overlap (microhomology) of 1 base pair (bp) or more was observed. The rearrangement
frequency declined by approximately 4-fold for each base of microhomology. This result
differed from the patterns seen in breast tumors, in which the most common junction
involved a microhomology of 2–3 bp28. Thus, mechanisms by which rearrangements are
generated may differ between prostate and breast cancer.
Detailed examination of these chromosomal rearrangements revealed a distinctive pattern of
balanced breaking and rejoining not previously observed in solid tumors: several genomes
contained complex inter- and intra-chromosomal events involving an exchange of
“breakpoint arms.” A mix of chimeric chromosomes was thereby generated, without
concomitant loss of genetic material (e.g., all breakpoints produced balanced translocations;
illustrated conceptually in Fig. 2a).
This “closed chain” pattern of breakage and rejoining was evident in each of the TMPRSS2-
ERG fusion-positive prostate cancers. In two such cases, both the TMPRSS2 and ERG
genomic loci were involved in a closed chain of breakpoints. For example, the TMPRSS2-
ERG gene fusion in PR-1701 was produced by a closed quartet of balanced translocations on
chromosomes 21 and 1 (Fig. 2b). The TMRPSS2-ERG gene fusion in PR-0581 occurred
within a closed trio of intrachromosomal rearrangements involving C21ORF45, ERG, and
TMPRSS2 (Supplementary Fig. 3).
One noteworthy closed chain of rearrangements harbored breakpoints situated independently
of TMPRSS2-ERG (Supplementary Fig. 4) but in close proximity to multiple known cancer
genes or orthologues. This chain (found in sample PR-2832) contained breakpoint pairs at
the following loci: (1) 60 bp from exon 6 of TANK binding kinase 1 (TBK1 or “NF-kB-
activating kinase”)29; (2) within the first intron of TP53 (7 kb upstream of translation start);
(3) 51 kb from MAP2K4 (a kinase recently shown to induce anchorage-independent growth
via mutations21); and (4) 3 kb from the ABL1 protooncogene (Fig. 2c). This striking
phenomenon suggests that complex translocations may dysregulate multiple genes in
parallel to drive prostate tumorigenesis.
Association of rearrangements and epigenetic marks
The closed chain pattern of chromosomal breakpoints also raised the possibility that
multiple genomic regions might become spatially co-localized prior to undergoing
rearrangement. Conceivably, such a phenomenon could reflect migration to “transcription
factories”—preassembled nuclear subcompartments that contain RNA polymerase II
holoenzyme30. In prostate cells, androgen signaling has been shown to induce co-
localization of TMPRSS2 and ERG, thereby allowing double-strand breaks to facilitate gene
fusion formation31–33. A role for transcription in the genesis of TMPRSS2-ERG in PR-1701
seems plausible, as genomic sequences of up to 240 bp are duplicated at the resulting fusion
junctions (Fig. 2b). Alternatively, chains of breakpoints might reflect the clustering of active
and inactive chromatin within the recently demonstrated fractal globule structure of nuclear
architecture34. Stimulated by these models, we considered whether the genomic regions
involved in prostate cancer rearrangements exhibited similarities in terms of either
transcriptional patterns or chromatin marks. Here, we employed published chromatin
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immunoprecipitation and massively parallel sequencing (ChIP-seq) data from VCaP, an
androgen-sensitive prostate cancer cell line that harbors the TMPRSS2-ERG gene fusion35.
Interestingly, the location of rearrangement breakpoints from the TMPRSS2-ERG fusion
positive tumor PR-2832 showed significant spatial correlation with various marks of open
chromatin in VCaP cells (Fig. 3 and Supplementary Fig. S5). These marks included ChIP-
seq peaks corresponding to RNA polymerase II (pol II, p = 1.0× 10−15), histone H3K4
trimethylation (H3K4me3, p = 3.1× 10−7), histone H3K36 trimethylation (H3K36me3, p =
3.5× 10−12), and histone H3 acetylation (H3ace, p = 9.5 × 10−12) (Fig. 3). Similar statistical
correlations were observed for peaks corresponding to AR (p = 1.1× 10−5), and ERG
binding sites (p = 4.9× 10−14) (Fig. 3 and Supplementary Table 6), consistent with the
substantial overlap between AR and ERG binding locations in VCaP cells35. (We did not
observe significant enrichment of either AR or ERG binding site sequences in the vicinity of
these breakpoints.) In the other ERG fusion-positive tumors (PR-0581 or PR-1701), the
correlations between breakpoints and ChIP-seq peaks were intermittently apparent, albeit
much less significant.
Surprisingly, rearrangement breakpoints from all four ETS fusion-negative tumors were
inversely correlated with these same marks of open chromatin and AR/ERG binding (Fig. 3
and Supplementary Fig. S5). In fact, breakpoints from two of four ETS-negative tumors
were significantly correlated with marks of histone H3K27 trimethylation (H3K27me3) in
VCaP cells, which denote inactive chromatin and transcriptional repression (Fig. 3). This
result suggested that somatic rearrangements might occur within closed chromatin in some
tumor cells, or that the epigenetic architecture or transcriptional program of some
TMPRSS2-ERG fusion positive cells differs markedly from that of ERG fusion-negative
cells. In support of the former, we observed a similar enrichment of PR-2832
rearrangements and depletion of fusion-negative rearrangements near marks of active
transcription profiled in several additional cell lines, including fusion-negative prostate
cancer cell lines LNCaP and PC-3 as well as three cell lines derived from non-prostate
lineages (Supplementary Fig. S5)35–37.
Based on these intriguing results, we performed similar analyses comparing the chromatin
state in VCaP cells to rearrangement patterns of other cancer types. No statistically
significant correlations or inverse correlations were observed between VCaP ChIP-seq data
and rearrangement breakpoints obtained from a melanoma cell line18, a small-cell lung
cancer cell line17, or a primary non-small cell lung tumor38 (Supplementary Fig. S5 and
Supplementary Table 6). However, rearrangements from 16 of 18 breast tumors and cell
lines examined28 exhibited a pattern of association similar to that observed in prostate tumor
PR-2832 (Supplementary Fig. S6). Notably, breakpoints in these tumors were also strongly
associated with estrogen receptor (ER) binding sites derived from the breast cancer cell line
MCF-739. Furthermore, we observed a strong association between ER ChIP-seq peaks from
MCF-7 and all VCaP ChIP-seq peaks corresponding to open chromatin, AR, and ERG
binding (p < 10−90; Supplementary Fig. S6). Thus, patterns of open chromatin may be
highly overlapping in some hormone-driven cancer cells. Such regions may correlate
significantly with sites of somatic rearrangement in cancers of the prostate, breast, and
possibly other tissues.
To examine whether processes linked to chromatin reorganization and DNA rearrangement
are also associated with increased mutation frequency, we tested for enrichment of point
mutations near regions of ChIP-seq peaks and rearrangement breakpoints. We observed a
significantly reduced prevalence of point mutations near marks of VCaP active transcription
—and slight enrichment of mutations in closed chromatin—in all 7 prostate tumors
(Supplementary Fig. S7). This pattern is consistent with both negative selection and
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transcription-coupled DNA repair. Additionally, we observed a significant enrichment of
mutations near rearrangement breakpoints in 5 of 7 prostate tumors (Supplementary Fig.
S7). Although the increased rate of mutations near rearrangements may conceivably reflect
activation-induced cytodine deaminase (AID) in the double strand break repair process31,40,
we did not observe a significant overrepresentation of any one class of mutation among
those located near breakpoints.
Recurrent rearrangements involving CADM2
Sixteen genes harbored a somatic rearrangement in at least 2 prostate tumors
(Supplementary Table 7), and four contained rearrangements in 3 of 7 tumors. In addition to
TMPRSS2 and ERG, the latter included CSMD3 and CADM2. These genes were rearranged
at a frequency beyond that expected by chance, even after correcting for gene size
(Supplementary Table 8). CSMD3 encodes a giant gene that contains multiple CUB and
sushi repeats. However, we did not observe additional CSMD3 rearrangements by
fluorescence in situ hybridization (FISH) in an independent analysis of 94 prostate tumors
(Supplementary Fig. S8).
CADM2 encodes a nectin-like member of the immunoglobulin-like cell adhesion molecules.
Several nectin-like proteins exhibit tumor suppressor properties in various contexts.
Analysis of SNP array-derived copy number profiles of tumors and cell lines41,42 suggests
that CADM2 does not reside near a fragile site (Supplementary Fig. S9). At the same time,
the complexity of CADM2 rearrangements (Fig. 4a) suggested that a simple FISH validation
approach might prove insufficient to determine the overall frequency of CADM2 disruption.
Nevertheless, we screened an independent cohort of 90 additional prostate tumors using a
“break-apart” FISH assay designed to query the CADM2 locus (Supplementary Fig. S8).
CADM2 aberrations were detected in 6/90 samples (5 rearrangements and 1 copy gain; Fig.
4b). These results confirmed that CADM2 is recurrently disrupted in prostate cancer,
although they likely represent a lower bound for the true prevalence of CADM2 alteration in
this malignancy.
Rearrangements disrupting PTEN and MAGI2
Two prostate tumors contained breakpoints within the PTEN tumor suppressor gene6 (Fig.
4c). In both cases, the rearrangements generated heterozygous deletions that were confirmed
by FISH analysis (Supplementary Fig. S10). In one tumor (PR-0581), PTEN rearrangement
co-occurred with a dinucleotide insertion within the PTEN coding sequence (described
above).
Two additional tumors harbored rearrangements disrupting the MAGI2 gene, which encodes
a PTEN-interacting protein43,44 (Fig. 4c). In one tumor (PR-0508), two independent but
closely aligned inversion events (marking both ends of a 450-kilobase inverted sequence)
affected the MAGI2 locus. In the other tumor (PR-2832), two long-range intrachromosomal
inversions were observed, raising the possibility of heterogeneous subclones harboring
independent MAGI2 rearrangements. Thus, 4 of 7 tumors harbored rearrangements predicted
to inactivate PTEN or MAGI2, including all three tumors harboring TMPRSS2-ERG
rearrangements. Although a tumor suppressor function for MAGI2 has not been established
previously, this gene was recently shown to undergo rearrangement in the genome of a
melanoma cell line18, another tumor type in which PTEN loss is prevalent. In principle,
genomic rearrangements that subvert PTEN function either directly or indirectly (e.g.,
through loss of MAGI2) might dysregulate the PI3 kinase pathway in prostate cancer.
Whereas both PTEN rearrangements involved chromosomal copy loss, the MAGI2
rearrangements were balanced events (Supplementary Fig. S11). Like CSMD3 and CADM2,
Berger et al. Page 6
Nature. Author manuscript; available in PMC 2011 August 10.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
MAGI2 does not appear to reside near a fragile site (Supplementary Fig. S9). We screened
88 independent prostate tumors using FISH inversion probes and identified 3 additional
samples harboring similar inversions, each of which was wild type for PTEN disruption
(Fig. 4d and Supplementary Fig. S8). As with CADM2 above, these FISH findings may
underestimate the true frequency of MAGI2 disruption in prostate cancer.
We further analyzed the PTEN and MAGI2 loci using high-density SNP arrays obtained
from 66 primary prostate cancers. As shown in Supplementary Figure S11, focal somatic
deletions affecting the PTEN locus were commonly observed in these tumors, as expected.
Interestingly, no SCNAs were observed at the MAGI2 locus in either prostate tumor found to
contain MAGI2 rearrangements by genome sequencing (Supplementary Fig. S11).
Conceivably, this region may also harbor genes whose loss would be deleterious to prostate
cancer cells. More generally, these findings suggest that extensive shotgun paired-end
sequencing (as opposed to lower-resolution approaches) may be required to elaborate the
compendium of genes targeted by somatic alterations in prostate cancer.
Discussion
This study represents the first whole genome sequencing analysis of human prostate cancer.
Systematic genome characterization efforts have often focused primarily on gene-coding
regions to identify “driver” or “druggable” alterations45–47. In contrast, the high prevalence
of recurrent gene fusions has highlighted chromosomal rearrangements as critical initiating
events in prostate cancer2,3. Genome sequencing data indicate that complex rearrangements
may enact pivotal gain- and loss-of-function driver events in primary prostate
carcinogenesis. Moreover, many rearrangements may occur preferentially in genes that are
spatially localized together with transcriptional or chromatin compartments, perhaps
initiated by DNA strand breaks and erroneous repair. The complexity of “closed chain” and
other rearrangements suggests that complete genome sequencing—as opposed to approaches
focused on exons or gene fusions—may be required to elaborate the spectrum of
mechanisms directing prostate cancer genesis and progression.
A positive correlation exists between the location of breakpoints in ERG-positive tumor
cells and open chromatin in VCaP cells, and also between breakpoints present in ERG-
negative cells and VCaP regions of closed chromatin. This suggests that breakpoints may
preferentially occur within regions of open chromatin in some ERG-positive tumor cells
while raising alternate possibilities for the genesis of breakpoints in ERG-negative cells.
Conceivably, somatic rearrangements may occur within regions of closed chromatin in
ERG-negative tumor cells. Alternately, ERG-negative tumor cells may have distinct
transcriptional or chromatin patterns, with many regions that are closed in VCaP being open
in these cells. Clustering of breakpoints within active regions might also reflect selection for
functionally consequential rearrangements during tumorigenesis. The relative contribution
of these aspects to tumorigenesis will likely be informed by additional integrative analyses
of epigenetic and structural genomic datasets across many tumor types.
Previous studies of genetically engineered mouse models have shown that the combination
of ERG dysregulation and PTEN loss triggers the formation of aggressive prostate
tumors48,49. This same combination identifies a subtype of human prostate cancer
characterized by poor prognosis50. The discovery of MAGI2 genomic rearrangements in
prostate cancer suggests that interrogating both the PTEN and MAGI2 loci might improve
prognostication and patient stratification for clinical trials of PI3 kinase pathway inhibitors.
Additional mutated genes discovered in this study also suggest interesting therapeutic
avenues. For example, the presence of point mutations involving chromatin modifying genes
and the HSP70/HSP90 chaperone complex raises the possibility that these cellular processes
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may represent targetable dependencies in some prostate tumors. Overall, complete genome
sequencing of large numbers of relapsing primary and metastatic prostate cancers promises
to define a genetic cartography that assists in tumor classification, defines mechanisms of
carcinogenesis, and identifies new targets for therapeutic intervention.
Methods Summary
The complete genomes of seven prostate tumors and patient-matched normal samples were
sequenced to approximately 30-fold haploid coverage on an Illumina GA II sequencer. DNA
was extracted from patient blood and from tumors following radical prostatectomy, and was
subjected to extensive quality control procedures to monitor DNA structural integrity,
genotype concordance, and tumor purity and ploidy. Standard paired-end libraries (~400bp
inserts) were sequenced as 101bp paired-end reads. Raw sequencing data were processed by
Illumina software and passed to the Picard pipeline, which produced a single BAM file for
each sample storing all reads with well-calibrated quality scores together with their
alignments to the reference genome. BAM files for each tumor/normal sample pair were
analyzed by the Firehose pipeline to characterize the full spectrum of somatic mutations in
each tumor, including base pair substitutions, short insertions and deletions, and large-scale
structural rearrangements. A subset of base pair mutations and rearrangements were
validated using independent technologies in order to assess the specificity of the detection
algorithms. Fluorescence in situ hybridization (FISH) was also performed for selected
recurrent rearrangements. The locations of all rearrangement breakpoints were compared to
previously published chromatin immunoprecipitation (ChIP) binding peaks from related cell
types to test for global associations between rearrangements and a range of epigenetic
marks.
A complete description of the materials and methods is provided in the Supplementary
Information. All Illumina sequence data have been deposited in dbGaP
(http://www.ncbi.nlm.nih.gov/gap) and are available at accession phs000330.v1.p1.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Graphical representation of 7 prostate cancer genomes. Each Circos plot12 depicts the
genomic location in the outer ring and chromosomal copy number in the inner ring (red =
copy gain; blue = copy loss). Interchromosomal translocations and intrachromosomal
rearrangements are shown in purple and green, respectively. Genomes are organized
according to the presence (top row) or absence (bottom row) of the TMPRSS2-ERG gene
fusion.
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Figure 2.
Complex structural rearrangements in prostate cancer. (a) Schematic of “closed chain”
pattern of chromosomal breakage and rejoining. Breaks are induced in a set of loci (left),
followed by an exchange of free ends without loss of chromosomal material (middle),
leading to the observed pattern of balanced (copy neutral) translocations involving a closed
set of breakpoints (right). (b) Complex rearrangement in prostate PR-1701. TMPRSS2-ERG
is produced by a closed quartet of balanced rearrangements involving 4 loci on
chromosomes 1 and 21. Top: Each rearrangement is supported by the presence of discordant
read pairs in the tumor genome but not the normal genome (colored bars connected by blue
lines). Thin bars represent sequence reads; directionality represents mapping orientation on
the reference genome. Figures are based on the Integrative Genomics Viewer
(http://www.broadinstitute.org/igv). Bottom: Schematic of breakpoints and balanced
translocations. Hatched lines indicate sequences that are duplicated in the derived
chromosomes at the resulting fusion junctions. (c) Complex rearrangement in prostate
PR-2832 involving breakpoints and fusions at 9 distinct genomic loci. Hatched lines indicate
sequences that are duplicated or deleted in the derived chromosomes at the resulting fusion
junctions. For breakpoints in intergenic regions, the nearest gene in each direction is shown.
In addition to the sheer number of regions involved, this complex rearrangement is notable
for the abundance of breakpoints in or near cancer related genes, such as TBK1, MAP2K4,
TP53, and ABL1.
Berger et al. Page 12
Nature. Author manuscript; available in PMC 2011 August 10.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 3.
Association between rearrangement breakpoints and genome-wide transcriptional/histone
marks in prostate cancer. ChIP-Seq binding peaks were defined previously for the
TMPRSS2-ERG positive (ERG+) prostate cancer cell line VCaP35. For each genome,
enrichment of breakpoints within 50 kb of each set of binding peaks was determined relative
to a coverage-matched simulated background (see Methods). ERG+ prostate tumors are in
black; ETS-negative prostate tumors are in white. Enrichment is displayed as the ratio of the
observed breakpoint rate to the background rate near each indicated set of ChIP-Seq peaks.
Rearrangements in ETS-negative tumors are depleted near marks of active transcription
(AR, ERG, H3K4me3, H3K36me3, Pol II, and H3ace) and enriched near marks of closed
chromatin (H3K27me3). P-values were calculated according to the binomial distribution and
are displayed in Supplementary Figure S5 and Supplementary Table 6. Significant
associations passing a false discovery rate cutoff of 5% are marked with an asterisk.
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Figure 4.
Disruption of CADM2 and the PTEN pathway by rearrangements. (a) Location of intragenic
breakpoints in CADM2. (b) CADM2 break-apart demonstrated by FISH in an independent
prostate tumor. (c) Location of intragenic breakpoints in PTEN (top) and MAGI2 (bottom).
(d) MAGI2 inversion demonstrated by FISH in an independent prostate tumor, using probes
flanking MAGI2 (red and green) and an external reference probe also on chromosome 7q
(green). The probes and strategy for detecting novel rearrangements by FISH are
diagrammed in Supplementary Figure S8.
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